Artificial platelets suppressing deep vein thrombosis via competitive adhesion.
Artificial platelets targeting the STING pathway reduced thrombosis in mice by 30%, suggesting a potential new strategy for DVT treatment pending human trials.
Where it sits
this study against the rest of the elamipretide corpusSummary and findings
The study investigated the use of artificial platelets (Pm@Fng) to suppress deep vein thrombosis (DVT) in a mouse model. Pm@Fng, loaded with forsythoside A, targeted the STING - NLRP3 pathway to reduce thrombosis by 30% (p<0.001). The approach leverages competitive adhesion to mitigate pathological platelet adhesion.
Abstract
Deep vein thrombosis (DVT) remains a therapeutic challenge, primarily driven by pathological platelet adhesion at sites of vascular injury mediated by endothelial adhesion molecule overexpression. However, the molecular mechanisms underlying endothelial-dependent pathological platelet adhesion remain elusive. Here, integrating single-cell RNA sequencing (scRNA-seq) and functional validation, we identified aberrant activation of the stimulator of interferon genes (STING) as a critical driver of endothelial dysfunction and pathological platelet adhesion. Using STING knockout mice, we confirmed its central role in promoting a prothrombotic microenvironment via the NOD-like receptor family pyrin domain-containing 3 (NLRP3) inflammasome. Targeting this pathway, we identified forsythoside A (FA) as a potent STING inhibitor and constructed artificial platelets (Pm@Fng) via photopolymerization-membrane extrusion technology. Pm@Fng, consisting of FA-loaded nanogels cloaked with activated platelet membrane vesicles (APMVs), exhibited enhanced glycoprotein Ib alpha (GPIbα) -mediated binding affinity to von Willebrand factor (vWF), competitively blocking pathological platelet adhesion. Under thrombotic microenvironment (acidic pH and high reactive oxygen species), FA was released to modulate the STING - NLRP3 pathway, suppressing adhesion molecule expression. In a mouse DVT model, Pm@Fng rapidly targeted the endothelium, noticeably reducing thrombosis by 30% (p < 0.001) and preserving endothelial integrity. By exploiting competitive adhesion principles, this study presents a novel therapeutic strategy for DVT and other endothelial injury-related diseases.
Background
Deep vein thrombosis (DVT) is a significant therapeutic challenge due to pathological platelet adhesion at vascular injury sites. This study addresses the molecular mechanisms of endothelial-dependent platelet adhesion, focusing on the STING pathway's role in promoting a prothrombotic environment. Understanding these mechanisms could lead to novel therapeutic strategies for DVT and related conditions.
Methods
The study utilized single-cell RNA sequencing and functional validation to explore the role of the STING pathway in endothelial dysfunction. STING knockout mice were used to confirm the pathway's involvement in a prothrombotic microenvironment. Artificial platelets (Pm@Fng) were constructed using photopolymerization-membrane extrusion technology, loaded with forsythoside A, and tested in a mouse DVT model.
Results
In the mouse DVT model, Pm@Fng targeted the endothelium and reduced thrombosis by 30% (p<0.001). The artificial platelets demonstrated enhanced binding affinity to von Willebrand factor, competitively blocking pathological platelet adhesion. Forsythoside A was released under thrombotic conditions, modulating the STING - NLRP3 pathway and suppressing adhesion molecule expression.
Interpretation
The study presents a novel approach to DVT treatment by targeting the STING pathway with artificial platelets. While the 30% reduction in thrombosis is statistically significant, its clinical relevance remains uncertain without human data. The findings align with existing literature on the STING pathway's role in thrombosis but require further validation in clinical settings.
Key findings
- 30% reduction in thrombosis in mouse DVT model (p<0.001).
- Forsythoside A identified as a potent STING inhibitor.
- Pm@Fng enhanced GPIbα-mediated binding to vWF.
- Artificial platelets released FA under thrombotic conditions.
- STING knockout mice confirmed prothrombotic microenvironment role.
Limitations
- mouse model only, no human data
- preclinical findings
- mechanistic focus, not clinical outcomes